<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04548700</url>
  </required_header>
  <id_info>
    <org_study_id>HE071-CSP-011</org_study_id>
    <nct_id>NCT04548700</nct_id>
  </id_info>
  <brief_title>Liposomal Mitoxantrone Hydrochloride Injection,Cyclophosphamide, Vincristine and Prednisone in the Treatment of PTCL</brief_title>
  <official_title>Clinical Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of Liposomal Mitoxantrone Hydrochloride Injection Combined With Cyclophosphamide, Vincristine and Prednisone in the Treatment of Untreated PTCL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicentre, open-label, single-arm, phase Ib clinical study to evaluate the&#xD;
      safety, tolerability, efficacy and pharmacokinetics of liposomal mitoxantrone hydrochloride&#xD;
      in combination with Cyclophosphamide, Vincristine and Prednisone in the frontline treatment&#xD;
      of patients with peripheral T cell lymphoma (PTCL).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is to investigate the safety, tolerability, efficacy and pharmacokinetics of&#xD;
      liposomal mitoxantrone hydrochloride in combination with Cyclophosphamide, Vincristine and&#xD;
      Prednisone in the frontline treatment of patients with PTCL by conducting in two stages,&#xD;
      Dose-finding stage and Dose-expansion stage.In Dose-finding stage, patients with&#xD;
      treatment-naïve PTCL will be assigned to receive sequentially higher doses of liposomal&#xD;
      mitoxantrone hydrochloride ranging from 12 to 18 mg/m2 plus Cyclophosphamide, Vincristine and&#xD;
      Prednisone (28 days per cycle). The dose escalation will follow the classic 3+3 design. The&#xD;
      recommended Phase 2 dose (RP2D) of liposomal mitoxantrone hydrochloride will be determined&#xD;
      according to the Dose-finding results. In Dose-expansion stage, additional patients will be&#xD;
      recruited into two groups, the Q4W group（28 days per cycle）and the Q3W group（21 days per&#xD;
      cycle）, to receive liposomal mitoxantrone hydrochloride at the RP2D combined with&#xD;
      Cyclophosphamide, Vincristine and Prednisone. All patients will receive the treatment for the&#xD;
      planned 6 cycles or until disease progression or unacceptable drug-related adverse events.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 24, 2020</start_date>
  <completion_date type="Anticipated">October 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 15, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-finding stage: The incidence of dose limited toxicities (DLTs)</measure>
    <time_frame>Cycle 1 (28 days)</time_frame>
    <description>To identify the DLTs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-finding stage:The incidence of AE and SAE</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>To identify the incidence of AE and SAE, abnormalities in clinical laboratory assessments, ECGs, echocardiography, vital sign assessments, and physical exams</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-expansion stage: The incidence of AE and SAE</measure>
    <time_frame>up to 18-24 weeks</time_frame>
    <description>To identify the incidence of AE and SAE, abnormalities in clinical laboratory assessments, ECGs, echocardiography, vital sign assessments, and physical exams</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose-finding stage: complete response(CR) rate</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>To investigate the preliminary antitumor efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-finding stage: duration of complete response（DoCR）</measure>
    <time_frame>Throughout study completion,an average of 18 months</time_frame>
    <description>To investigate the preliminary antitumor efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-finding stage: overall response rate (ORR)</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>To investigate the preliminary antitumor efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-finding stage: progression-free survival（PFS）</measure>
    <time_frame>Throughout study completion,an average of 18 months</time_frame>
    <description>To investigate the preliminary antitumor efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-finding stage：the pharmacokinetic parameters Cmax</measure>
    <time_frame>Cycle 1 to Cycle 6(each cycle is 28 days)</time_frame>
    <description>To investigate the PK characteristics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-finding stage：the pharmacokinetic parameters AUC0-t</measure>
    <time_frame>Cycle 1 to Cycle 6(each cycle is 28 days)</time_frame>
    <description>To investigate the PK characteristics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-expansion stage: CR rate</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>To investigate the preliminary antitumor efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-expansion stage: DoCR</measure>
    <time_frame>Throughout study completion,an average of 18 months</time_frame>
    <description>To investigate the preliminary antitumor efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-expansion stage: ORR</measure>
    <time_frame>up to 18-24 weeks</time_frame>
    <description>To investigate the preliminary antitumor efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-expansion stage: PFS</measure>
    <time_frame>Throughout study completion,an average of 18 months</time_frame>
    <description>To investigate the preliminary antitumor efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-expansion stage: the pharmacokinetic parameters Cmax</measure>
    <time_frame>Cycle 1(each cycle is 21or28 days)</time_frame>
    <description>To investigate the PK characteristics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-expansion stage: the pharmacokinetic parameters AUC0-t</measure>
    <time_frame>Cycle 1(each cycle is 21or28 days)</time_frame>
    <description>To investigate the PK characteristics</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">63</enrollment>
  <condition>Treatment-naïve</condition>
  <condition>Peripheral T Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Dose-finding and dose-expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose-finding stage: Patients with treatment-naïve PTCL will receive sequentially higher doses of liposomal mitoxantrone hydrochloride in combination with Cyclophosphamide, Vincristine and Prednisone for 6 cycles (planned) (28 days per cycle). The initial dose of liposomal mitoxantrone hydrochloride is 12 mg/m2.&#xD;
Dose-expansion stage: Patients with treatment-naïve PTCL will receive liposomal mitoxantrone hydrochloride at RP2D in combination with Cyclophosphamide, Vincristine and Prednisone for 6 cycles (planned) (28 or 21 days per cycle).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dose-finding stage: Liposomal mitoxantrone hydrochloride, Cyclophosphamide, Vincristine and Prednisone</intervention_name>
    <description>Drug: Liposomal mitoxantrone hydrochloride (12 mg/m2, 15 mg/m2, 18 mg/m2) will be administered by an intravenous infusion on day 1 of each 28-day cycle.&#xD;
Drug: Cyclophosphamide (750 mg/m2) will be administered by an intravenous infusion on day 1 of each 28-day cycle.&#xD;
Drug: Vincristine (1.4 mg/m2 with 2 mg as the maximum dose) will be administered by an intravenous injection on day 1 of each 28-day cycle.&#xD;
Drug: Prednisone (100 mg/d) will be taken orally from day 1 to day 5 of each 28-day cycle.</description>
    <arm_group_label>Dose-finding and dose-expansion</arm_group_label>
    <other_name>Part1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dose-expansion stage: Liposomal mitoxantrone hydrochloride, Cyclophosphamide, Vincristine and Prednisone</intervention_name>
    <description>Drug: Liposomal mitoxantrone hydrochloride (at RP2D) will be administered by an intravenous infusion on day 1 of each 28- or 21-day cycle.&#xD;
Drug: Cyclophosphamide (750 mg/m2) will be administered by an intravenous infusion on day 1 of each 28- or 21-day cycle.&#xD;
Drug: Vincristine (1.4 mg/m2 with 2 mg as the maximum dose) will be administered by an intravenous injection on day 1 of each 28- or 21-day cycle.&#xD;
Drug: Prednisone (100 mg/d) will be taken orally from day 1 to day 5 of each 28- or 21-day.</description>
    <arm_group_label>Dose-finding and dose-expansion</arm_group_label>
    <other_name>Part2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects fully understand and voluntarily participate in this study and sign informed&#xD;
             consent&#xD;
&#xD;
          2. Age ≥18, ≤70years, no gender limitation&#xD;
&#xD;
          3. Histologically confirmed diagnosis of treatment-naïve PTCL. Eligible histologies are&#xD;
             limited to the following: Peripheral T-cell lymphoma - not otherwise specified&#xD;
             (PTCL-NOS),Angioimmunoblastic T-cell lymphoma (AITL), ALK -positive Anaplastic Large&#xD;
             cell Lymphoma（ALCL）, ALK-negative ALCL; Other PTCL that investigators consider to be&#xD;
             appropriate to be enrolled&#xD;
&#xD;
          4. PTCL with fluorodeoxyglucose (FDG) avidity that can be evaluated by PET/CT&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-1&#xD;
&#xD;
          6. The following required baseline laboratory data: Absolute neutrophil count (ANC)&#xD;
             ≥1.5×109/L, Platelet count (PLT) ≥75×109/L, Hemoglobin(HB)≥ 80g/L, Total bilirubin&#xD;
             (TBIL) ≤1.5X upper limit of normal (ULN) , Alanine aminotransferase (ALT) and&#xD;
             aspartate aminotransferase (AST) ≤2.5X ULN , Serum creatinine (Scr) ≤1.5X ULN&#xD;
&#xD;
          7. Females of childbearing potential must have a negative serum beta human chorionic&#xD;
             gonadotrophin (β-hCG) pregnancy test result prior to enrollment and must agree to use&#xD;
             an effective contraception method for the duration of the study treatment and 12&#xD;
             months after the last dose of study therapy&#xD;
&#xD;
          8. Males of reproductive potential must agree to use an effective contraceptive method&#xD;
             for the duration of the study treatment and 12 months after the last dose of study&#xD;
             therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Current diagnosis of any of the following: extranodal natural killer/T-cell lymphoma,&#xD;
             nasal type(NKTCL), Mycosis fungoides (MF)/ Sézary syndrome (SS), Primary cutaneous&#xD;
             ALCL，and Adult T-cell leukemia/lymphoma&#xD;
&#xD;
          2. Leukemic phase of lymphoma (≥20% lymphoma cell in the bone marrow), or central nervous&#xD;
             system (CNS) involvement, or hemophagocytic syndrome&#xD;
&#xD;
          3. Life expectancy &lt; 6 months&#xD;
&#xD;
          4. History of allergy to anthracyclines or liposomes&#xD;
&#xD;
          5. History of contraindications to cyclophosphamide, vincristine or prednisone&#xD;
&#xD;
          6. Prior anti-lymphoma therapy except short-term or low-dose corticosteroid treatment&#xD;
&#xD;
          7. Impaired cardiac function or significant cardiac disease&#xD;
&#xD;
          8. Positive test results for HBsAg antigen and HBV-DNA, or hepatitis C virus (HCV)&#xD;
             antibody or human immunodeficiency virus (HIV) antibody&#xD;
&#xD;
          9. Major surgery within 4～6weeks prior to screening. Or have a surgical schedule during&#xD;
             the study&#xD;
&#xD;
         10. A serious infection within 4 weeks prior to screening and not suitable for the study&#xD;
             according to the judgment of the investigator&#xD;
&#xD;
         11. Uncontrolled hypertension at screening&#xD;
&#xD;
         12. Uncontrolled diabetes at screening&#xD;
&#xD;
         13. History of active visceral hemorrhage in the recent 3 months prior to screening&#xD;
&#xD;
         14. History of other tumors in the past five years prior to screening. Patients with&#xD;
             curable tumors (such as skin basal cell carcinoma, carcinoma in situ of the cervix or&#xD;
             of the breast, intramucosal carcinoma in situ of the gastrointestinal tract or&#xD;
             localized prostate cancer) could be enrolled after completely cured&#xD;
&#xD;
         15. History of solid organ transplantation&#xD;
&#xD;
         16. Known psychiatric disorders or cognitive disorder&#xD;
&#xD;
         17. Known alcohol or drug abuse&#xD;
&#xD;
         18. Pregnant or breastfeeding women&#xD;
&#xD;
         19. Not suitable for this study as determined by the investigator due to other reasons&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huiqiang Huang, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xuefang Xia</last_name>
    <phone>18963980673</phone>
    <email>xiaxuefang@mail.ecspc.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huiqiang Huang, Doctor</last_name>
      <phone>13808885154</phone>
      <email>huanghq@sysucc.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 28, 2020</study_first_submitted>
  <study_first_submitted_qc>September 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2020</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

